Product Update

Deltex Medical Group PLC
19 September 2005


19 September 2005

             Deltex Medical Group plc ('Deltex Medical' / 'Company')

  London teaching hospitals evaluating use of CardioQ(TM) in operating theatres

Deltex Medical, the AIM listed haemodynamic monitoring company, today announces
that three major London teaching hospitals have each committed to evaluate its
CardioQ oesophageal Doppler monitors in operating theatres.  The Board
understands that if these evaluations confirm that routine use of the CardioQ
allows the hospitals to improve both the quality and cost effectiveness of
surgical care, the doctors leading the projects expect that the respective
hospitals will make available sufficient funds to implement the CardioQ as a
standard of care for moderate and major surgery.

The Company is supporting these evaluations according to the training and data
collection needs of each of the three hospitals.  In two cases, this includes
lending monitors to the hospitals for the duration of the evaluation and, in the
third case, providing a limited number of free-of-charge probes following the
recent purchase by the hospital of three CardioQ monitors exclusively for use in
its operating theatres.

Deltex Medical's Chief Executive, Andy Hill, commented:

'It is encouraging that three London teaching hospitals have independently
decided to evaluate their ability to deliver the proven clinical and economic
benefits of haemodynamically optimising patients using the CardioQ.  At a time
when most UK NHS hospitals are trying to minimise or totally avoid any
expenditure on new equipment, this demonstrates that investment in our products
is now increasingly seen as a high priority.

'The London teaching hospitals have a long history of setting standards which
others follow, so we would expect successful conclusions to these evaluations to
help unblock the funding of CardioQs in a significant number of other UK
hospitals.'


For further information, please contact:-

Deltex Medical Group plc
01243 774 837
Nigel Keen, Chairman
Andy Hill, Chief Executive
Ewan Phillips, Finance Director

Financial Dynamics
0207 831 3113
David Yates/ John Gilbert


Notes for Editors

Deltex Medical manufactures and markets the CardioQ monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs.  This causes medical
complications including peripheral and major organ failure which can lead to
death.  Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself.  Using fluids and drugs, guided by the CardioQ, to optimise the amount
of circulating blood significantly reduces post-operative complications allowing
patients to make a faster, more complete recovery and return home earlier.

The CardioQ incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ provides clinicians with the ability to haemodynamically
optimise critically ill patients and those undergoing routine moderate to major
surgery through the controlled administration of fluid and drugs. Haemodynamic
optimisation has been scientifically proven to improve the speed and quality of
patient recovery and reduce hospital stay.

There are already over 1,250 CardioQs currently in use in hospitals worldwide
and distribution arrangements are in place in over 30 countries. In addition,
there are currently more than 90 clinical publications on the use of the CardioQ
which have repeatedly:-

  • validated the results of the Monitor against known standards for measuring
    cardiac output, demonstrating that the technology works

  • proved that the CardioQ works in a wide range of surgical procedures

  • demonstrated that the Company's technology provides significant health and
    economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.


                      This information is provided by RNS
            The company news service from the London Stock Exchange